Even talazoparib has been used to treat cancer patients with mutations in BRCA1/2, but recent findings have reported that in some TNBC cell lines, PARP inhibitors are effective in non BRCA1/2 mutation carriers [16]. Here, BRCA1 is linked to cancer.